Sunovion refreshes Lunesta campaign

Share this article:
Sunovion refreshes Lunesta campaign
Sunovion refreshes Lunesta campaign

Sunovion Pharmaceuticals quietly mothballed a Lunesta TV ad that drew FDA scrutiny, in favor of a spot that reprises the sleep drug's familiar mascot.

On air nationally since Thanksgiving, the latest commercial features the Luna moth coming to rest on the backs of those with insomnia, as a voiceover states, “Sleep well, on the wings of Lunesta.” Interpublic Group agencies ICC, which is part of Lowe Healthcare, and Deutsch collaborated on the spot.

It's part of a renewed effort to educate patients and physicians on the importance of treating insomnia, said Tricia Moriarty, Sunovion director of commercial communications. She told MM&M that the launch of the new ad “was not related in any way to FDA's concerns but part of a fresh new campaign.”

In June 2010 DDMAC cited a previous Lunesta commercial for misleading claims. That ad featured a woman “fighting for sleep” in a bed-turned-boxing ring and implied superiority over other medications, despite a lack of clinical evidence to that effect, while overstating the mechanism of action, DDMAC wrote.

Moriarty said the boxing-bed ad was updated in July to address the untitled letter, and the revised spot was aired from August-November by the company, then known as Sepracor. Sepracor changed its name to Sunovion in October, a year after being acquired by Japan's Dainippon Sumitomo Pharma.

According to SDI/Kantar Media, for the 12 months ending September 2010, Sepracor increased DTC advertising spend by 78% to about $49 million. That's more than double the $22.9 million spent by Sanofi-Aventis on consumer messaging for rival sleep drug Ambien CR, which cut its spend 86% during the same period.

Lunesta posted third-quarter US sales of $154 million, vs. $151 million in the second quarter.

Moriarty said the new ad, which also appears on, may be used in other digital media channels, and those decisions will be made at a later date.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...